158 related articles for article (PubMed ID: 31842643)
1. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia.
Pejsa V; Lucijanic M; Vrkljan Vuk A; Stoos-Veic T; Jaksic O; Jonjic Z; Pirsic M; Prka Z; Ivic M; Fazlic Dzankic A; Mitrovic Z
Leuk Lymphoma; 2020 Apr; 61(4):934-939. PubMed ID: 31842643
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Greil R; Tedeschi A; Moreno C; Anz B; Larratt L; Simkovic M; Gill D; Gribben JG; Flinn IW; Wang Z; Cheung LWK; Nguyen AN; Zhou C; Styles L; Demirkan F
Ann Hematol; 2021 Jul; 100(7):1733-1742. PubMed ID: 34018029
[TBL] [Abstract][Full Text] [Related]
3. Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
Dawson K; Moran M; Guindon K; Wan H
Clin J Oncol Nurs; 2016 Apr; 20(2):E41-8. PubMed ID: 26991722
[TBL] [Abstract][Full Text] [Related]
4. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
Jean GW; Comeau JM
Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
6. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of obinutuzumab-associated toxicities: Australian experience.
Snowden A; Hayden I; Dixon J; Gregory G
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():15-27. PubMed ID: 26681665
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Herishanu Y; Levi S; Kamdjou T; Bornstein Y; Ram R; Benyamini N; Varon D; Avivi I; Perry C
Br J Haematol; 2021 Jan; 192(1):e1-e4. PubMed ID: 33095444
[No Abstract] [Full Text] [Related]
9. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.
García-Muñoz R; Aguinaga L; Feliu J; Anton-Remirez J; Jorge-Del-Val L; Casajús-Navasal A; Nebot-Villacampa MJ; Daroca-Fernandez I; Domínguez-Garrido E; Rabasa P; Panizo C
Immunotherapy; 2018 Mar; 10(6):491-499. PubMed ID: 29562857
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
Hoy SM
Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I
Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377
[TBL] [Abstract][Full Text] [Related]
17. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.
Jain P; Kanagal-Shamanna R; Wierda W; Ferrajoli A; Keating M; Jain N
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):151-154. PubMed ID: 27352257
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab in chronic lymphocytic leukemia.
Dupuis J
Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Byrd JC; Flynn JM; Kipps TJ; Boxer M; Kolibaba KS; Carlile DJ; Fingerle-Rowson G; Tyson N; Hirata J; Sharman JP
Blood; 2016 Jan; 127(1):79-86. PubMed ID: 26472752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
